Riliprubart clinical trials
Also written SAR445088.
How each study uses riliprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the riliprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Immunoglobulins, Intravenous (1) · Immunoglobulin G (1) · Adrenal Cortex Hormones (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test riliprubart, phase 3 first.
Studies
Open first, then newest update. How each study uses riliprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDPEnrolling by invitationPhase 3SanofiNCT06859099Written as Riliprubart Prefilled Pen (PFP)
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingPhase 3SanofiNCT06290141Written as riliprubart
- BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Active, not recruitingPhase 2SanofiNCT05156710Written as BIVV020 (SAR445088)
- A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkActive, not recruitingPhase 3SanofiNCT06290128Written as Riliprubart
- Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedPhase 2Bioverativ, a Sanofi companyNCT04658472Written as SAR445088 (IV)
- A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin DiseaseCompletedPhase 1Bioverativ, a Sanofi companyNCT04269551Written as BIVV020
- Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088TerminatedPhase 1Bioverativ, a Sanofi companyNCT04802057Written as SAR445088
- A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)CompletedPhase 2Bioverativ, a Sanofi companyNCT04669600Written as SAR445088 (BIVV020)
Codes
What other systems call riliprubart · ClinicalTrials.gg INT016815
- UNII (FDA) I31869XDP8RILIPRUBARTOne source FDA
- NCI Thesaurus C199103RiliprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | I31869XDP8 | RILIPRUBART | One source FDA |
| NCI Thesaurus | C199103 | Riliprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.